• Explore /
  • Poster
  • / ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev).

ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev).

Abstract Poster

Authors

null

Wen Wee Ma

Division of Medical Oncology, Mayo Clinic, Rochester, MN

Wen Wee Ma , Fang-Shu Ou , Jenny Jing Li , Nguyen H. Tran , Hani M. Babiker , Alexander Revzin , Haidong Dong , Garth D. Nelson , Andrew Ness , Carissa E. Schuster , Jingquan Jia , Tanios S. Bekaii-Saab

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT05168163

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4170)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4170

Abstract #

TPS4170

Poster Bd #

150b

Abstract Disclosures

Similar Posters

First Author: Takeshi Terashima

First Author: Kazuomi Ueshima

First Author: Arndt Vogel

First Author: Daneng Li